Algert Global’s Rigel Pharmaceuticals RIGL Stock Holding History

Algert Global’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,755	Closed	-$44K	–	1254
2022 Q3	$44K	Hold	3,755	–	–	﹤0.01%	1137
2022 Q2	$42K	Sell	3,755 -10,604	-74%	-$213K	﹤0.01%	1161
2022 Q1	$429K	Buy	+14,359	New	+$389K	0.03%	864
2021 Q2	–	Sell	-1,519	Closed	-$52K	–	508
2021 Q1	$52K	Buy	+1,519	New	+$60.2K	0.02%	424
2017 Q1	–	Sell	-7,225	Closed	-$172K	–	359
2016 Q4	$172K	Sell	7,225 -26,141	-78%	-$749K	0.05%	301
2016 Q3	$1.23M	Buy	33,366 +8,632	+35%	+$247K	0.35%	101
2016 Q2	$552K	Buy	24,734 +11,545	+88%	+$287K	0.22%	179
2016 Q1	$274K	Buy	13,189 +7,693	+140%	+$190K	0.1%	294
2015 Q4	$167K	Hold	5,496	–	–	0.08%	299
2015 Q3	$136K	Hold	5,496	–	–	0.08%	292
2015 Q2	$176K	Hold	5,496	–	–	0.1%	286
2015 Q1	$196K	Buy	5,496 +4,184	+319%	+$115K	0.11%	281
2014 Q4	$30K	Hold	1,312	–	–	0.02%	292
2014 Q3	$25K	Hold	1,312	–	–	0.02%	276
2014 Q2	$48K	Buy	+1,312	New	+$44.6K	0.03%	284

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Algert Global's RIGL Position: Q4 2022 in Review

Algert Global sold out of Rigel Pharmaceuticals (RIGL) in Q4 2022, closing a stake of 3,755 shares — an estimated $44K sold.

Algert Global first reported a position in RIGL in Q2 2014 and held it in 15 quarters. The position peaked at $1.23M in Q3 2016. 118 funds tracked by Wall St. Rank hold RIGL as of Q4 2022.

Algert Global reported no remaining Rigel Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Algert Global sold 3,755 Rigel Pharmaceuticals shares in Q4 2022, an estimated $44K.
Algert Global first reported a position in Rigel Pharmaceuticals in Q2 2014 and held it in 15 quarters.
Algert Global's Rigel Pharmaceuticals position peaked at $1.23M in Q3 2016.
118 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2022.

Based on Algert Global's 13F filing for Q4 2022, filed 14 Feb 2023.